Prospective and Multicentric Cohort Study of Severe and Very Severe Chronic Obstructive Pulmonary Disease (COPD) in Brazil (SCOPe).

Recruiting Observational Study
COPD (Chronic Obstructive Pulmonary Disease)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
693 (estimated)
Sponsor
Hospital Israelita Albert Einstein · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Chronic obstructive pulmonary disease (COPD) is prevalent (8-20%) and is one of the leading causes of mortality. In 2019 according to WHO it was the third highest cause of death worldwide. In 2019 in Brazil respiratory diseases (Chapter J in the ICD10) were the third cause of death (176.073) with COPD (J44) accounting for 45.163 deaths (25,6% of respiratory and 3% overall). There is an upward tren…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Severe, very severe and symptomaitc COPD, according to GOLD definition: exposure, FEV1/FVC ratio \<0,7: * GOLD B (mMRC\>=2, CAT\>=10), OR * GOLD E (\>=2 moderate exacerbations or 1 severe), OR * GOLD 3 and 4 (FEV1 \<50%). Exclusion Criteria: Severe interstitial lung disease (…
Contacts

Francisco JN Mazon, MD

+55 11 21511233

francisco.mazon@einstein.br

CONTACT

Henrique A R Fonseca, ScD

+55 11 21511233

henrique.fonseca@einstein.br

CONTACT